PTEN and neoplasm: Next, an analysis of correlations between the expression of all cancer driver TFs and the drugs identified above (as linked to the mutational status of proto-oncogenes or tumor suppressors) revealed significant differences relative to non-cancer driver TFs (Wilcoxon rank test p = 3.7 × 10−10, excluding the coincident CTNNB1 and PTEN; Fig. 4e).